Jason T Lewis

US Patent:

20130039848, Feb 14, 2013

Filed:

Jul 2, 2010

Appl. No.:

13/381209

Inventors:

Michelle Bradbury - New York NY, US
Ulrich Wiesner - Ithaca NY, US
Oula Penate Medina - New York NY, US
Andrew Burns - Niskayuna NY, US
Jason Lewis - New York NY, US
Steven Larson - New York NY, US

Assignee:

CORNELL UNIVERSITY - Ithaca NY
SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH - New York NY

International Classification:

A61K 49/00
A61K 49/06
A61K 49/04
A61K 9/14
A61K 39/395
A61K 31/7088
A61K 48/00
A61K 31/56
A61K 31/713
A61K 31/7105
G01N 21/64
A61P 35/00
A61P 31/04
A61P 31/00
A61P 39/06
A61P 37/06
A61P 7/02
A61P 9/08
A61P 29/00
A61K 51/12
B82Y 5/00
B82Y 15/00

US Classification:

424 137, 424 96, 424 93, 424 94, 424490, 4241781, 514 44 A, 514 44 R, 514169, 435 723, 977773, 977906, 977927, 977928, 977930

Abstract:

The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as polyethylene glycol) (PEG) The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo The nanoparticle may further be conjugated to a ligand capable of binding to a cellular component associated with the specific cell type, such as a tumor marker A therapeutic agent may be attached to the nanoparticle Radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle to permit the nanoparticle to be detectable by various imaging techniques.

US Patent:

20220348648, Nov 3, 2022

Filed:

Jul 8, 2020

Appl. No.:

17/622404

Inventors:

- New York NY, US
Jason LEWIS - New York NY, US
Abdul KHAN - New York NY, US
David ANDREW - New York NY, US
Xinlei CHEN - New York NY, US
Ivo LORENZ - New York NY, US

International Classification:

C07K 16/28
C12N 15/63
A61P 35/00

Abstract:

The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to delta-like protein 3 (DLL3). The antibodies of the present technology are useful in methods for detecting and treating a DLL3-associated cancer in a subject in need thereof.

US Patent:

20220305149, Sep 29, 2022

Filed:

Aug 28, 2020

Appl. No.:

17/638512

Inventors:

- New York NY, US
Teja Muralidhar KALIDINDI - New York NY, US
Sang-Gyu LEE - New York NY, US
Steven M. LARSON - New York NY, US
Jason S. LEWIS - New York NY, US
Serge LYASHCHENKO - New York NY, US
Eva BURNAZI - New York NY, US

International Classification:

A61K 51/10
A61P 35/00
A61K 33/243
A61K 51/04
A61K 49/00

Abstract:

The present disclosure provides compositions and methods for the detection and treatment of cancer. Specifically, the compositions of the present technology include novel radiohalogenated (e.g., radioiodinated) PSMA targeting agents and methods of using the same in diagnostic imaging as well as radiation therapy.

US Patent:

20220275017, Sep 1, 2022

Filed:

Mar 14, 2022

Appl. No.:

17/694180

Inventors:

- New York City NY, US
Eric K. CHEA - Flushing NY, US
Derek S. TAN - New York NY, US
Jason S. LEWIS - New York NY, US
Jeffrey R. GARDNER - New York NY, US

International Classification:

C07H 15/256
A61K 39/39
A61K 45/06
A61K 31/7024
C07H 15/18
C07H 15/24
A61K 31/704

Abstract:

Truncated triterpene saponin analogues containing a trisaccharide or tetrasaccharide ester are disclosed. Also disclosed are pharmaceutical compositions comprising truncated saponin analogues and synthetic methods of producing the truncated saponin analogues. Another aspect of the present application relates to a method for immunizing a subject, comprising administering to the subject the pharmaceutical composition comprising a minimal saponin analogue and an antigen.

US Patent:

20230037294, Feb 9, 2023

Filed:

Oct 7, 2022

Appl. No.:

17/961761

Inventors:

- New York NY, US
- Ithaca NY, US
- Columbia MO, US
Barney Yoo - New York NY, US
Jason Lewis - New York NY, US
Ulrich Wiesner - Ithaca NY, US
Kai Ma - Ithaca NY, US

International Classification:

A61K 47/69
A61K 51/12
A61K 51/04
A61K 51/10
A61K 45/06
A61K 49/00
A61K 49/18
C07K 16/40

Abstract:

Disclosed herein are nanoparticle immunoconjugates useful for therapeutics and/or diagnostics. The immunoconjugates have diameter (e.g., average diameter) no greater than 20 nanometers (e.g., as measured by dynamic light scattering (DLS) in aqueous solution, e.g., saline solution). In certain embodiments, the conjugates are silica-based nanoparticles with single chain antibody fragments attached thereto.

US Patent:

20230040245, Feb 9, 2023

Filed:

Aug 4, 2022

Appl. No.:

17/881350

Inventors:

- New York NY, US
David Ulmert - Brooklyn NY, US
Jason Lewis - New York NY, US
Michael J. Evans - New York NY, US
Hans Lija - New York NY, US

International Classification:

A61K 51/10
G01N 33/574
A61B 5/00

Abstract:

The present invention provides methods of monitoring and measuring tumor-associated free PSA (“fPSA”) with antibody polypeptides as an indication of androgen receptor signaling. In a particular embodiment, the methods may be used to assess the efficacy of anti-androgen and/or general anti-cancer treatments. The present invention also provides various methods and compositions relating to antibodies that are specific for tumor-associated or intratumoral fPSA. For example, the present invention provides compositions, including pharmaceutical compositions, comprising anti-fPSA antibodies, or fragments or characterisitic portions thereof. The present invention further provides various therapeutic and/or diagnostic methods of using anti-fPSA antibodies and/or compositions.

US Patent:

20210138091, May 13, 2021

Filed:

Jul 21, 2020

Appl. No.:

16/934881

Inventors:

- New York NY, US
Naga Vara Kishore Pillarsetty - Jackson Heights NY, US
Jason S. Lewis - New York NY, US
Steven M. Larson - New York NY, US
Tony Taldone - Forest Hills NY, US
Mary L. Alpaugh - Teaneck NJ, US

International Classification:

A61K 51/04
G01N 33/50
G01N 33/574
A61K 31/52

Abstract:

This invention concerns various methods of using labeled HSP90 inhibitors to improve treatment of cancer patients with HSP90 inhibitors, including ex vivo and in vivo methods for determining whether a tumor will likely respond to therapy with an HSP90 inhibitor.

US Patent:

20210070796, Mar 11, 2021

Filed:

Apr 20, 2020

Appl. No.:

16/853393

Inventors:

- New York City NY, US
Eric K. Chea - Flushing NY, US
Derek S. Tan - New York NY, US
Jason S. Lewis - New York NY, US
Jeffrey R. Gardner - New York NY, US

International Classification:

C07H 15/256
A61K 39/39
A61K 45/06
A61K 31/7024
C07H 15/18
C07H 15/24
A61K 31/704

Abstract:

Truncated triterpene saponin analogues containing a trisaccharide or tetrasaccharide ester are disclosed. Also disclosed are pharmaceutical compositions comprising truncated saponin analogues and synthetic methods of producing the truncated saponin analogues. Another aspect of the present application relates to a method for immunizing a subject, comprising administering to the subject the pharmaceutical composition comprising a minimal saponin analogue and an antigen.